학술논문
COX-2 selective inhibitors--important lessons learned.
Document Type
Article
Author
Source
Subject
*DRUG side effects
*CYCLOOXYGENASE 2 inhibitors
*PAIN medicine
*
*
Language
ISSN
0140-6736
Abstract
Examines the safety of the COX-2 inhibitor rofecoxib, commonly used to treat chronic pain. Details of the development, marketing, and prescription of COX-2 inhibitors; Decision of the Merck Pharmaceutical company to withdraw rofecoxib from the market due to safety concerns; Details of a study on potential adverse cardiovascular effect of the drug; Claim that the pharmaceutical industry failed to properly regulate the safety of rofecoxib and other COX-2 inhibitors; Impact of the withdrawal of rofecoxib on the pharmaceutical industry.